Caraco Pharmaceutical Laboratories Ltd

Caraco Pharmaceutical Laboratories — Investor Presentation (September 2006)

22 slides from Caraco Pharmaceutical Laboratories's investor presentation, Sep 6, 2006

  1. Slide 1: Caraco Pharmaceutical Laboratories, Ltd.

    Caraco Pharmaceutical Laboratories, Ltd.

  2. Slide 2: Safe Harbor

    Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual re

  3. Slide 3: Caraco Overview

    Caraco Overview What sets us apart from the pack??? Size of our product portfolio vs. the size of company Experienced management team Vertically integrated via Sun API’s Disciplined management Ability to service our customers’ immediate needs Capable of creating markets that previously did not exist

  4. Slide 4: Overview

    Caraco Overview What sets us apart from the pack??? Low cost production Size plays to our advantage Ability to penetrate the market Building to fit the current environment Improved customer mix Removal of barriers, execution

  5. Slide 5: Annual Historical Results

    Caraco Pharmaceutical Laboratories, LTD Annual Historical Results (in US $ millions)

  6. Slide 6: Quarterly Analysis

    Caraco Pharmaceutical Laboratories, LTD Quarterly Analysis (in US $ millions)

  7. Slide 7: Sales for Calendar 2005

    Caraco Pharmaceutical Laboratories, LTD SALES for Calendar 2005 (in US $ millions)

  8. Slide 8: Sales Calendar 2005 vs. 2006 Year-to-Date

    Caraco Pharmaceutical Laboratories, LTD SALES Calendar 2005 vs. 2006 Year-to-Date (in US $ millions)

  9. Slide 9: Sales for Fiscal 2006

    Caraco Pharmaceutical Laboratories, LTD SALES for Fiscal 2006 (in US $ millions)

  10. Slide 10: Product Development Quarterly Filings (ANDAs)

    Caraco Pharmaceutical Laboratories, LTD Product Development Quarterly Filings (ANDAS)

  11. Slide 11: Clozapine Sales Update & Web Registry

    Caraco Pharmaceutical Laboratories, LTD Clozapine Sales Update & Web Registry Development Caraco successfully launched www.caracoclozapine.com on March th 2006 New confirmed customer commitments Distributor Class of Trade Large distributor buying group Large managed care (HMO) player Two of Big Thre

  12. Slide 12: Product Market Share Trends

    Caraco Pharmaceutical Laboratories, LTD Product Market Share Trends Caraco is currently marketing 23 generic pharmaceuticals and 1 brand product 3 of the 23 products were launched in fiscal 2005-2006 14 of the 23 products are in the top 3 of generic market share In 2006 Caraco was named the 3 rd fas

  13. Slide 13: Sales by Customer Class, Apr-Jun 2005 vs 2006

    Apr 2005 - June 2005 Apr 2006 - June 2006 BChain- Chain- 126MM 242MM ODist- ODist - 358MM 648MM Whole - Whole - 334MM 442MM C1Mg Care- CIMg Care- 226MM 443MM Govt - CiGovt- 690MM 828MM

  14. Slide 14: Expansion

    Expansion Current facility is 80,000 sq ft and lease another 62,000 sq ft Currently retrofit is in process to allow for additional lab, QA, manufacturing, employees; 2006 average 200 million tablets per month Need to build 80,000 - 100,000 sq ft facility or move to 250,000 sq. ft cGMP facility for c

  15. Slide 15: Accomplishments 2006

    Accomplishments 2006 FDA approvals of Fluvoxamine, Carbamazapine, Tramadol with APAP, Clozapine 50mg, tentative approval on Zolpidem Tartrate, tentative approval on Carvedilol Filed 10 products with the FDA in fiscal 2006 5th consecutive year of growth Improved technical team with additional staff a

  16. Slide 16: Accomplishments 2006

    Accomplishments 2006 Increased manufacturing capacity by 35% Record tablets produced in March (247 million tablets) Improved growth trend from 30% in fiscal 2004 to 38% in fiscal 2006 despite additional price erosion of 4.75% Maintained gross profit of 49% which is above the generic industry average

  17. Slide 17: Accomplishments 2006

    Accomplishments 2006 Completed manufacturing expansion within facility increasing usable sq ft to 80,000 sq. ft. Increased total footprint to 142,000 sq ft Awarded summary judgment in favor of Caraco on Tramadol w/APAP litigation Enhanced core team with additional staff and succession planning. Move

  18. Slide 18: Accomplishments 2006

    Accomplishments 2006 Increased training in cGMP Third fastest growing generic pharmaceutical company in US* Award of Top 500 fastest growing technology companies Ranked 96th by Deloitte & Touche Award of Future 50 representing the top 50 growth companies in Metro Detroit based on sales and employmen

  19. Slide 19: Product Litigation

    Product Litigation Lexapro – Teva lost infringement case and is set to appeal; possible upside if Caraco prevails Prandin – First to file position Provigil – Determine next steps to monetize Ultracet – Ortho filed suit based on new patent effective August 1st which we certified we do not infringe; o

  20. Slide 20: Drivers 2007

    Drivers 2007 Approvals - Baclofen, Meloxicam, Glipizide Approvals pending Increase / Maintain Share Increase and Close Alternate Development Projects Work on Co-Development

  21. Slide 21: Drivers 2007

    Drivers 2007 Expand current development streams and pursue new opportunities Expansion of current facilities Improve packaging Continue staff improvements and succession planning

  22. Slide 22: Thank You

    CARACO Thank You

Caraco Pharmaceutical Laboratories — Investor Presentation (September 2006) on 6ix